Sodium iodoacetate

Sodium iodoacetate is a specific inhibitor of GAPDH and has glycolysis inhibitory activity. In addition, sodium iodoacetate can induce osteoarthritis and related pain models in experimental animals[1][2][3][4].

Product Specifications

CAS Number

[305-53-3]

Product Name Alternative

Iodoacetic acid sodium salt

UNSPSC

12352200

Hazard Statement

H301, H314

Target

Biochemical Assay Reagents

Type

Biochemical Assay Reagents

Related Pathways

Others

Field of Research

Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/sodium-iodoacetate.html

Purity

99.91

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : ≥ 100 mg/mL

Smiles

O=C(O[Na])CI

Molecular Formula

C2H2INaO2

Molecular Weight

207.93

Precautions

H301, H314

References & Citations

[1]Xu, Y. et al. Glycolysis in Innate Immune Cells Contributes to Autoimmunity. Frontiers in Immunology, 13. |[2]Na, H. et al. Soluble CCR2 gene therapy controls joint inflammation, cartilage damage, and the progression of osteoarthritis by targeting MCP-1 in a monosodium iodoacetate (MIA) -induced OA rat model. Journal of Translational Medicine, 20 (1) |[3]Kobayashi K, et al. Sodium iodoacetate-induced experimental osteoarthritis and associated pain model in rats[J]. Journal of Veterinary Medical Science, 2003, 65 (11) : 1195-1199.|[4]Güler N, et al. Sodium iodoacetate induced osteoarthrosis model in rabbit temporomandibular joint: CT and histological study (part I) [J]. International journal of oral and maxillofacial surgery, 2011, 40 (11) : 1289-1295.